AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17615018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Brief intervention by dental professionals providing feedback on oral symptoms and dental treatments relevant to smoking.
Number of subjects: 797
Study 17615018 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention Group (NG) - No intervention provided.
Number of subjects: 797
Study 17615018 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (IG and NG combined)
Number of subjects: 797
Study 17615018 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not ready to quit (IG and NG combined)
Number of subjects: 797
Study 14767365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS) monitoring
Number of subjects: 0
Study 14767365 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation assessment using Ramsay score
Number of subjects: 0
Study 11956262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 60 mg/m² on days 1, 8, and 15 repeated every 4 weeks (group 1; n = 16)
Number of subjects: 32
Study 11956262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m² on days 1 and 15 of a 4-week cycle (group 2; n = 16)
Number of subjects: 32
Study 11956262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with oxaliplatin
Number of subjects: 32
Study 10450425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis against Plasmodium falciparum malaria
Number of subjects: 106
Study 10450425 — intervention group
Group type: COMPARATOR
Intervention: Placebo only or placebo and iron supplementation
Number of subjects: 106
Study 10450425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis alone or in combination with iron
Number of subjects: 106
Study 10450425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 106
Study 7541448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (5 micrograms/kg/d)
Number of subjects: 120
Study 7541448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7541448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 120
Study 2473880 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant stimuli presented at angles of 10, 45, or 90 degrees to the right of the standards.
Number of subjects: 12
Study 2473880 — intervention group
Group type: COMPARATOR
Intervention: Standard stimuli presented directly in front of the subjects.
Number of subjects: 12
Study 795372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin + Cephalothin or Gentamicin
Number of subjects: 127
Study 31687762 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER)
Number of subjects: 21105
Study 31687762 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (LDER)
Number of subjects: 21105
Study 31687762 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 31687762 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (HDER, LDER, Warfarin)
Number of subjects: 21105
Study 28597176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist monitoring with CARAT questionnaire every 2 weeks and counselling on disease management, ICS adherence, and inhalation technique
Number of subjects: 80
Study 28597176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist monitoring
Number of subjects: 80
Study 28597176 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Monitoring Intervention (EMI) users
Number of subjects: 80
Study 28597176 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Standard care without pharmacist monitoring
Number of subjects: 80
Study 26009784 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral programs (Comet, Cope, Incredible Years)
Number of subjects: 908
Study 26009784 — intervention group
Group type: COMPARATOR
Intervention: Nonbehavioral program (Connect)
Number of subjects: 908
Study 26009784 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting interventions (all programs)
Number of subjects: 908
Study 23916584 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy (group I)
Number of subjects: 40
Study 23916584 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh surgery (group II)
Number of subjects: 40
Study 21168122 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg
Number of subjects: 12
Study 21168122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19573556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (250 mg) plus Vitamin B12 (100 microg), folic acid (300 microg), Vitamin B6 (12.5 mg) and l‐arginine (100 mg) daily for 1 year
Number of subjects: 65
Study 19573556 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 65
Study 17380560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) and graduated compression (GC)
Number of subjects: 0
Study 17380560 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 14679114 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus gemcitabine-cisplatin
Number of subjects: 103
Study 14679114 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin alone
Number of subjects: 103
Study 14679114 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus gemcitabine-cisplatin (HER2 3+ or FISH-positive subgroup)
Number of subjects: 103
Study 11119461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite atrial pacing
Number of subjects: 20
Study 11119461 — intervention group
Group type: COMPARATOR
Intervention: Right atrial pacing
Number of subjects: 20
Study 9211444 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 12
Study 9211444 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 12
Study 9211444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7957512 — intervention group
Group type: EXPERIMENTAL
Intervention: M(r) 2264 Cl 2 x 5 mg i.v.
Number of subjects: 0
Study 7957512 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 x 10 mg i.v.
Number of subjects: 0
Study 7957512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3054373 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, surgery, postoperative radiotherapy
Number of subjects: 158
Study 3054373 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (surgery and postoperative radiotherapy)
Number of subjects: 158
Study 4583181 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk substitute
Number of subjects: 0
Study 29162290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention using the 'Good Palliative‐Geriatric Practice' algorithm and STOPP/START criteria
Number of subjects: 490
Study 29162290 — intervention group
Group type: COMPARATOR
Intervention: Routine standard of care (Control group)
Number of subjects: 490
Study 29162290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 490
Study 28663392 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular Metal (TM) acetabular component
Number of subjects: 42
Study 28663392 — intervention group
Group type: COMPARATOR
Intervention: Cemented acetabular component
Number of subjects: 42
Study 25873093 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (free phone communication, data submission, motivational messages)
Number of subjects: 3825
Study 25873093 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory community engagement arm
Number of subjects: 3825
Study 25873093 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 3825
Study 23968849 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal neuropsychological intervention (attention retraining, teaching compensatory strategies, psychoeducation, psychological support, and homework assignments) conducted once a week in 60-minute sessions during thirteen consecutive weeks
Number of subjects: 98
Study 22182309 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (7 core contacts with a provider of government funded 'Well Child' care over 2 years)
Number of subjects: 800
Study 22182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Food, Activity and Breastfeeding group (8 extra parent contacts over the first 2 years of life)
Number of subjects: 800
Study 22182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (at least 3 extra parent contacts over the first 6 months of life)
Number of subjects: 800
Study 22182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (all extra contacts)
Number of subjects: 800
Study 19719910 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg once daily
Number of subjects: 61
Study 19719910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiviral treatment)
Number of subjects: 61
Study 21242071 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron odor
Number of subjects: 35
Study 15937632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education programme (PEP) consisting of a home visit and four 1-hour teaching sessions.
Number of subjects: 170
Study 15937632 — intervention group
Group type: COMPARATOR
Intervention: Control practices (standard care).
Number of subjects: 170
Study 12223140 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine
Number of subjects: 196
Study 12223140 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine with Ara‐AMP
Number of subjects: 196
Study 12223140 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐a1b
Number of subjects: 196
Study 12223140 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 196
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fexofenadine HCl
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fexofenadine HCl
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg fexofenadine HCl
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg fexofenadine HCl
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose administration
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary elimination
Number of subjects: 24
Study 9818712 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+) and S(‐) fexofenadine
Number of subjects: 24
Study 7646652 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic flurbiprofen; appropriate doses not specified
Number of subjects: 0
Study 2575765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavain (2 x 200 mg daily)
Number of subjects: 52
Study 2575765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 3.0 mg b.i.d. for 4 weeks
Number of subjects: 70
Study 30768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11557486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol (15 mg/kg of body weight) administered orally once daily to subjects with AIDS and healthy volunteers.
Number of subjects: 40
Study 31924955 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined height (1 standard deviation higher, equivalent to 6.5 cm)
Number of subjects: 0
Study 31924955 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for potential mediators (lipids, blood pressure, glycaemic traits, body mass index, socio‐economic status)
Number of subjects: 0
Study 31924955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function (measured by FEV1 and FVC)
Number of subjects: 0
Study 31924955 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 0
Study 29974725 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapic combination of L-Methionine, Hibiscus sabdariffa, and Boswellia serrata (1 tablet in the morning and 1 tablet in the evening for 7 days)
Number of subjects: 93
Study 29974725 — intervention group
Group type: COMPARATOR
Intervention: Short term antibiotic treatment according to international guidelines recommendations
Number of subjects: 93
Study 25620034 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises with positive expiratory pressure (10-15 cmH2O), 30 slow deep breaths twice a day for 2 months
Number of subjects: 48
Study 25620034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breathing exercises)
Number of subjects: 48
Study 23953402 — intervention group
Group type: EXPERIMENTAL
Intervention: i-scan imaging
Number of subjects: 95
Study 23953402 — intervention group
Group type: EXPERIMENTAL
Intervention: acetic acid
Number of subjects: 95
Study 23953402 — intervention group
Group type: COMPARATOR
Intervention: random biopsies
Number of subjects: 95
Study 22744417 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional strength training (TS)
Number of subjects: 16
Study 22744417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mATPase histochemistry and MHC immunohistochemistry
Number of subjects: 16
Study 22744417 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (C)
Number of subjects: 16
Study 20228974 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaMatrix membrane
Number of subjects: 6
Study 20228974 — intervention group
Group type: COMPARATOR
Intervention: Autogenous gingival graft
Number of subjects: 6
Study 17403707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 36-40 microg kg‐1
Number of subjects: 60
Study 17403707 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 0 microg kg‐1 (control group)
Number of subjects: 60
Study 17403707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil doses of 15, 30, 45 microg kg‐1
Number of subjects: 60
Study 14978366 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/Meperidine (MM)
Number of subjects: 100
Study 14978366 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/Placebo (MP)
Number of subjects: 100
Study 12195604 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 0
Study 9814496 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese urban black women (BW)
Number of subjects: 20
Study 9814496 — intervention group
Group type: COMPARATOR
Intervention: Obese urban white women (WW)
Number of subjects: 20
Study 7657272 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month treatment starting with 6 MU three times a week, decreasing dose based on serum ALT (Group A: 59 cases)
Number of subjects: 174
Study 7657272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of 3 MU three times a week for 12 months (Group B: 61 cases)
Number of subjects: 174
Study 7657272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of 6 MU three times a week for 6 months (Group C: 54 cases)
Number of subjects: 174
Study 2503945 — intervention group
Group type: COMPARATOR
Intervention: Sublingual Nitroglycerin
Number of subjects: 78
Study 2503945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Nifedipine
Number of subjects: 78
Study 178838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mithramycin at a dose of 25 mug/kg/day for 21 days
Number of subjects: 96
Study 178838 — intervention group
Group type: COMPARATOR
Intervention: Best conventional care (Control)
Number of subjects: 96
Study 178838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mithramycin
Number of subjects: 96
Study 178838 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (not specifically evaluated in the study)
Number of subjects: 96
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-LIP diet
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-LIP diet
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-LIP diet
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% CP diet
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: LIP diets
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcass yield for females
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: HIP diets
Number of subjects: 4176
Study 30995312 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 and 28-LIP diets
Number of subjects: 4176
Study 28333342 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem (600 mg) + Amoxicillin/Clavulanic acid (500/125 mg)
Number of subjects: 36
Study 28333342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (10 mg/kg)
Number of subjects: 36
Study 28333342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (10 mg/kg) + Faropenem (600 mg) + Amoxicillin/Clavulanic acid (500/125 mg)
Number of subjects: 36
Study 26066063 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF serum levels in stable COPD
Number of subjects: 308
Study 26066063 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔVEGF (increase in VEGF over time) in ProCOLD cohort
Number of subjects: 308
Study 26066063 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔVEGF in ProCOLD cohort
Number of subjects: 308
Study 23862647 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/kg weekly intravenous alpha1-PI
Number of subjects: 30
Study 23862647 — intervention group
Group type: COMPARATOR
Intervention: 60 mg/kg weekly intravenous alpha1-PI
Number of subjects: 30
Study 23862647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 30
Study 21209124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise radical endoscopic resection (SRER)
Number of subjects: 47
Study 21209124 — intervention group
Group type: COMPARATOR
Intervention: Focal endoscopic resection followed by radiofrequency ablation (ER/RFA)
Number of subjects: 47
Study 18305082 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin 4%
Number of subjects: 60
Study 18305082 — intervention group
Group type: COMPARATOR
Intervention: HES 130/0.4 6%
Number of subjects: 60
Study 18305082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 18305082 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney function
Number of subjects: 60
Study 17290656 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual plus expert system intervention
Number of subjects: 1351
Study 17290656 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual alone
Number of subjects: 1351
Study 17290656 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based interventions
Number of subjects: 1351
Study 12207105 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided behaviour therapy (BT)
Number of subjects: 153
Study 12207105 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-guided behaviour therapy (BT)
Number of subjects: 153
Study 12207105 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy (BT)
Number of subjects: 153
Study 10483277 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative accelerated irradiation (PAIR) with a total dose of 32 Gy (2 x 2 Gy/d)
Number of subjects: 34
Study 10483277 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with a total dose of 60 Gy (K60)
Number of subjects: 34
Study 10483277 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (PAIR and conventional)
Number of subjects: 34
Study 8552931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sustained-release melatonin
Number of subjects: 0
Study 8552931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg fast-release melatonin
Number of subjects: 0
Study 8552931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg sustained-release melatonin (2-month treatment)
Number of subjects: 0
Study 8552931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1793876 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg aspirin per day
Number of subjects: 427
Study 1793876 — intervention group
Group type: COMPARATOR
Intervention: No aspirin or antiplatelet agents
Number of subjects: 427
Study 7011010 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus six cycles of adjuvant chemotherapy
Number of subjects: 318
Study 7011010 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 318
Study 7011010 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy alone or radiation therapy plus chemotherapy
Number of subjects: 318
Study 29209867 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied at 780 nm, masseter and temporal=5 J/cm2 (20 mW-0.5 W/cm2), TMJ area=7.5 J/cm2 (30 mW-0.8 W/cm2), eight sessions, twice a week.
Number of subjects: 64
Study 29209867 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 64
Study 29209867 — intervention group
Group type: COMPARATOR
Intervention: Without treatment (WT)
Number of subjects: 64
Study 29209867 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLLT
Number of subjects: 64
Study 29209867 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with low levels of anxiety, salivary cortisol below 10 ng/ml, and with contraceptive use
Number of subjects: 64
Study 28258052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic GPS-based measures of walkability and recreation area exposure
Number of subjects: 249
Study 28258052 — intervention group
Group type: COMPARATOR
Intervention: Static home-based measures of walkability and recreation area exposure
Number of subjects: 249
Study 26471311 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU oral D3 supplementation
Number of subjects: 30
Study 26471311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23616112 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing images of strongly liked red and green objects
Number of subjects: 0
Study 23616112 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing images of strongly disliked red and green objects
Number of subjects: 0